ClinicalTrials.gg

Program

GENSCI139

A development code. Also written as “GenSci139”.

Its studies are led by Changchun GeneScience Pharmaceutical.

Furthest: phase 1, since Sep 22, 20251 company-led study, 1 open or runningNext primary completion: Jul 7, 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Changchun GeneScience Pharmaceutical11 open or runningphase 1since Sep 22, 2025Sep 22, 2025Jul 7, 2028phase 1 · NCT07230977

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 22, 2025First study: phase 1 study in Advanced Solid TumorsFirst studyNCT07230977 · 280 planned · China

Ahead

  1. Jul 7, 2028Primary completion: phase 1 study in Advanced Solid TumorsNCT07230977

TargetBeta

EGFR →ERBB2 →read by rule
“GenSci139 is a bispecific antibody drug conjugate targeting EGFR and HER2.”study text, by rule · the study

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
sunvozertinibruleDizal Pharmaceuticalsphase 312
sevabertinibruleBayerphase 38
enozertinibruleoric-pharmaceuticalsphase 23
EGFR/HER2 Mutant-selective Inhibitor BH-30643ruleblossomhill-therapeuticsphase 21

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07230977Advanced Solid Tumors · China1RecruitingJul 7, 2028280

How it is read

Names in the registry

  • “GenSci139”, 1 entry

Codes read as this program: GENSCI139.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.